Cystic Fibrosis Gene Therapy in the UK and Elsewhere

Human Gene Therapy

Volumn 26, Issue 5, 2015, Pages 266-275

  Griesenbach, Uta ^a   Pytel, Kamila M ^a   Alton, Eric W F W ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; LENTIVIRUS VECTOR; MESSENGER RNA; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;

ARTICLE; CYSTIC FIBROSIS; GENE EXPRESSION; GENE MUTATION; GENE THERAPY; GENE TRANSFER; HUMAN; ION TRANSPORT; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; RNA VIRUS; UNITED KINGDOM; ANIMAL; GENE VECTOR; GENETICS; MUTATION;

ANIMALS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MUTATION;

EID: 84929730645     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2015.027     Document Type: Article

References (120)

1. Collawn JF, and Matalon S. CFTR and lung homeostasis. Am J Physiol Lung Cell Mol Physiol 2014;307:L917-L923.
2. Wang Y, Wrennall JA, Cai Z, et al. Understanding how cystic fibrosis mutations disrupt CFTR function: from single molecules to animal models. Int J Biochem Cell Biol 2014;52:47-57.
3. Boucher RC. Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu Rev Med 2007;58:157-170.
4. Naehrlich L, et al. Nasal potential difference measurements in diagnosis of cystic fibrosis: an international survey. J Cyst Fibros 2014;13:24-28.
5. Davies JC, et al. Potential difference measurements in the lower airway of children with and without cystic fibrosis. Am J Respir Crit Care Med 2005;171:1015-1019.
6. Rogers CS, et al. Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. Science 2008; 321:1837-1841.
7. Chen JH, et al. Loss of anion transport without increased sodium absorption characterizes newborn porcine cystic fibrosis airway epithelia. Cell 2010;143:911-923.
8. Pezzulo AA, et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 2012;487:109-113.
9. Goldstein W, and Doring G. Lysosomal enzymes from polymorphonuclear leukocytes and proteinase inhibitors in patients with cystic fibrosis. Am Rev Respir Dis 1986;134:49-56.
10. Nakamura H, Yoshimura K, McElvaney NG, et al. Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J Clin Invest 1992;89:1478-1484.
11. Haggie PM, and Verkman AS. Cystic fibrosis transmembrane conductance regulator-independent phagosomal acidification in macrophages. J Biol Chem 2007;282:31422-31428.
12. Di A, et al. CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat Cell Biol 2006;8:933-944.
13. Mueller C, et al. Lack of cystic fibrosis transmembrane conductance regulator in CD3+ lymphocytes leads to aberrant cytokine secretion and hyperinflammatory adaptive immune responses. Am J Respir Cell Mol Biol 2011;44:922-929.
14. Cystic Fibrosis Worldwide. www.cfww.org (last accessed May 11, 2015).
15. Cystic Fibrosis Registry. www.cysticfibrosis.org.uk/media/598466/annual-data-report-2013-jul14.pdf (last accessed April 28, 2015).
16. Kerem B, et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989;245:1073-1080.
17. Riordan JR, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245:1066-1073.
18. Rommens JM, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989; 245:1059-1065.
19. Cystic Fibrosis Mutation Database. www.genet.sickkids.on.ca/cftr/ (last accessed May 11, 2015).
20. Cystic Fibrosis Foundation. www.cff.org/research/TDN/ (last accessed May 11, 2015).
21. European Cystic Fibrosis Society https://www.ecfs.eu/ctn (last accessed May 11, 2015).
22. Ramsey BW, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365:1663-1672.
23. De Boeck K, et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J Cyst Fibros 2014;13:674-680.
24. Bell SC, De BK, and Amaral MD. New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls. Pharmacol Ther 2015;145C:19-34.
25. Oakland M, Sinn PL, and McCray PB, Jr. Advances in cell and gene-based therapies for cystic fibrosis lung disease. Mol Ther 2012;20:1108-1115.
26. Johnson LG, et al. Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat Genet 1992;2:21-25.
27. Zhang L, et al. CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium. PLoS Biol 2009;7:e1000155.
28. Potash AE, et al. Adenoviral gene transfer corrects the ion transport defect in the sinus epithelia of a porcine CF model. Mol Ther 2013;21:947-953.
29. Chu CS, Trapnell BC, Curristin S, et al. Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA. Nat Genet 1993;3:151-156.
30. Alton EW, et al. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet 1999;353:947-954.
31. Hyde SC, et al. Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis. Gene Ther 2000;7:1156-1165.
32. Johnson LG, Boyles SE, Wilson J, et al. Normalization of raised sodium absorption and raised calcium-mediated chloride secretion by adenovirus-mediated expression of cystic fibrosis transmembrane conductance regulator in primary human cystic fibrosis airway epithelial cells. J Clin Invest 1995;95:1377-1382.
33. Farmen SL, et al. Gene transfer of CFTR to airway epithelia: low levels of expression are sufficient to correct Cl - transport and overexpression can generate basolateral CFTR. Am J Physiol Lung Cell Mol Physiol 2005;289: L1123-L1130.
34. Quinton PM. Role of epithelial HCO3 transport in mucin secretion: lessons from cystic fibrosis. Am J Physiol Cell Physiol 2010;299:C1222-C1233.
35. Engelhardt JF, et al. Submucosal glands are the predominant site of CFTR expression in the human bronchus. Nat Genet 1992;2:240-248.
36. Kreda SM, et al. Characterization of wild-type and DF508 cystic fibrosis transmembrane regulator in human respiratory epithelia. Mol Biol Cell 2005;16:2154-2167.
37. Penque D, et al. Cystic fibrosis F508del patients have apically localized CFTR in a reduced number of airway cells. Lab Invest 2000;80:857-868.
38. Deriy LV, et al. Disease-causing mutations in the cystic fibrosis transmembrane conductance regulator determine the functional responses of alveolar macrophages. J Biol Chem 2009;284:35926-35938.
39. Painter RG, et al. CFTR Expression in human neutrophils and the phagolysosomal chlorination defect in cystic fibrosis. Biochemistry 2006;45:10260-10269.
40. Griesenbach U, and Alton EW. Moving forward: cystic fibrosis gene therapy. Hum Mol Genet 2013;22:R52-R58.
41. Volpers C, and Kochanek S. Adenoviral vectors for gene transfer and therapy. J Gene Med 2004;6 Suppl 1:S164-S171.
42. Saban SD, Silvestry M, Nemerow GR, et al. Visualization of a-helices in a 6-Ångstrom resolution cryoelectron microscopy structure of adenovirus allows refinement of capsid protein assignments. J Virol 2006;80:12049-12059.
43. Russell WC. Adenoviruses: update on structure and function. J Gen Virol 2009;90:1-20.
44. Brunetti-Pierri N, and Ng P. Progress and prospects: gene therapy for genetic diseases with helper-dependent adenoviral vectors. Gene Ther 2008;15:553-560.
45. Zabner J, Couture LA, Gregory RJ, et al. Adenovirusmediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 1993;75:207-216.
46. Crystal RG, et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 1994;8:42-51.
47. Knowles MR, et al. A controlled study of adenoviral-vectormediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med 1995;333:823-831.
48. Hay JG, McElvaney NG, Herena J, et al. Modification of nasal epithelial potential differences of individuals with cystic fibrosis consequent to local administration of a normal CFTR cDNA adenovirus gene transfer vector. Hum Gene Ther 1995;6:1487-1496.
49. Zabner J, et al. Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. J Clin Invest 1996;97:1504-1511.
50. Bellon G, et al. Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial. Hum Gene Ther 1997;8:15-25.
51. Harvey BG, et al. Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus. J Clin Invest 1999; 104:1245-1255.
52. Zuckerman JB, et al. A phase I study of adenovirusmediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis. Hum Gene Ther 1999;10:2973-2985.
53. Joseph PM, et al. Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. I. Methods, safety, and clinical implications. Hum Gene Ther 2001;12:1369-1382.
54. Perricone MA, et al. Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. II. Transfection efficiency in airway epithelium. Hum Gene Ther 2001;12:1383-1394.
55. Walters RW, et al. Basolateral localization of fiber receptors limits adenovirus infection from the apical surface of airway epithelia. J Biol Chem 1999;274:10219-10226.
56. Koehler DR, et al. Aerosol delivery of an enhanced helperdependent adenovirus formulation to rabbit lung using an intratracheal catheter. J Gene Med 2005;7:1409-1420.
57. Vetrini F, and Ng P. Gene therapy with helper-dependent adenoviral vectors: current advances and future perspectives. Viruses 2010;2:1886-1917.
58. Toietta G, et al. Reduced inflammation and improved airway expression using helper-dependent adenoviral vectors with a K18 promoter. Mol Ther 2003;7:649-658.
59. Koehler DR, et al. Protection of Cftr knockout mice from acute lung infection by a helper-dependent adenoviral vector expressing Cftr in airway epithelia. Proc Natl Acad Sci U S A 2003;100:15364-15369.
60. Mietzsch M, Broecker F, Reinhardt A, et al. Differential adeno-associated virus serotype-specific interaction patterns with synthetic heparins and other glycans. J Virol 2014;88:2991-3003.
61. Nonnenmacher M, and Weber T. Intracellular transport of recombinant adeno-associated virus vectors. Gene Ther 2012;19:649-658.
62. Penaud-Budloo M, et al. Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle. J Virol 2008;82:7875-7885.
63. Flotte TR, Afione SA, and Zeitlin PL. Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration. Am J Respir Cell Mol Biol 1994;11:517-521.
64. Kaeppel C, et al. A largely random AAV integration profile after LPLD gene therapy. Nat Med 2013;19:889-891.
65. Moss RB, et al. Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. Hum Gene Ther 2007;18:726-732.
66. Flotte TR, et al. Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter. J Biol Chem 1993;268:3781-3790.
67. Liu X, et al. Analysis of adeno-associated virus progenitor cell transduction in mouse lung. Mol Ther 2009;17:285-293.
68. Faust SM, et al. CpG-depleted adeno-associated virus vectors evade immune detection. J Clin Invest 2013;123: 2994-3001.
69. Vandenberghe LH, et al. Naturally occurring singleton residues in AAV capsid impact vector performance and illustrate structural constraints. Gene Ther 2009;16:1416-1428.
70. Li W, et al. Generation of novel AAV variants by directed evolution for improved CFTR delivery to human ciliated airway epithelium. Mol Ther 2009;17:2067-2077.
71. Flotte TR, et al. Dual reporter comparative indexing of rAAV pseudotyped vectors in chimpanzee airway. Mol Ther 2010;18:594-600.
72. Halbert CL, et al. Expression of human a1 -antitrypsin in mice and dogs following AAV6 vector-mediated gene transfer to the lungs. Mol Ther 2010;18:1165-1172.
73. Limberis MP, Vandenberghe LH, Zhang L, et al. Transduction efficiencies of novel AAV vectors in mouse airway epithelium in vivo and human ciliated airway epithelium in vitro. Mol Ther 2009;17:294-301.
74. Asokan A, Schaffer DV, and Samulski RJ. The AAV vector toolkit: poised at the clinical crossroads. Mol Ther 2012;20:699-708.
75. Allocca M, et al. Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice. J Clin Invest 2008;118:1955-1964.
76. Song Y, et al. Functional cystic fibrosis transmembrane conductance regulator expression in cystic fibrosis airway epithelial cells by AAV6.2-mediated segmental transsplicing. Hum Gene Ther 2009;20:267-281.
77. Yan Z, et al. A novel chimeric adenoassociated virus 2/ human bocavirus 1 parvovirus vector efficiently transduces human airway epithelia. Mol Ther 2013;21:2181-2194.
78. Schuster BS, et al. Overcoming the cystic fibrosis sputum barrier to leading adeno-associated virus gene therapy vectors. Mol Ther 2014;22:1484-1493.
79. Myint M, et al. In vivo evaluation of adeno-associated virus gene transfer in airways of mice with acute or chronic respiratory infection. Hum Gene Ther 2014;25:966-976.
80. Nathwani AC, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014;371:1994-2004.
81. Pierce EA, and Bennett J. The status of RPE65 gene therapy trials: safety and efficacy. Cold Spring Harb Perspect Med 2015 [Epub ahead of print]; DOI: 10.1101/cshperspect.a017285.
82. Pfizer. www.pfizer.com/news (last accessed May 11, 2015).
83. Sanofi-Genzyme. http://news.genzyme.com/ (last accessed May 11, 2015).
84. Zhang L, et al. a-Fetoprotein gene delivery to the nasal epithelium of nonhuman primates by human parainfluenza viral vectors. Hum Gene Ther 2010;21:1657-1664.
85. Henrickson KJ. Parainfluenza viruses. Clin Microbiol Rev 2003;16:242-264.
86. Ferrari S, et al. Sendai virus-mediated CFTR gene transfer to the airway epithelium. Gene Ther 2007;14:1371-1379.
87. Griesenbach U, et al. Validation of recombinant Sendai virus in a non-natural host model. Gene Ther 2010;18: 182-188.
88. Griesenbach U, et al. Effect of tolerance induction to immunodominant T-cell epitopes of Sendai virus on gene expression following repeat administration to lung. Gene Ther 2006;13:449-456.
89. Aiuti A, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 2013;341:1233151.
90. Biffi A, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 2013;341:1233158.
91. Palfi S, et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. Lancet 2014;383:1138-1146.
92. Segura MM, Mangion M, Gaillet B, et al. New developments in lentiviral vector design, production and purification. Expert Opin Biol Ther 2013;13:987-1011.
93. Limberis M, Anson DS, Fuller M, et al. Recovery of airway cystic fibrosis transmembrane conductance regulator function in mice with cystic fibrosis after single-dose lentivirus-mediated gene transfer. Hum Gene Ther 2002; 13:1961-1970.
94. Kobayashi M, Iida A, Ueda Y, et al. Pseudotyped lentivirus vectors derived from simian immunodeficiency virus SIVagm with envelope glycoproteins from paramyxovirus. J Virol 2003;77:2607-2614.
95. Sinn PL, Arias AC, Brogden KA, et al. Lentivirus vector can be readministered to nasal epithelia without blocking immune responses. J Virol 2008;82:10684-10692.
96. Patel M, Giddings AM, Sechelski J, et al. High efficiency gene transfer to airways of mice using influenza hemagglutinin pseudotyped lentiviral vectors. J Gene Med 2013;15:51-62.
97. Cmielewski P, Anson DS, and Parsons DW. Lysophosphatidylcholine as an adjuvant for lentiviral vector mediated gene transfer to airway epithelium: effect of acyl chain length. Respir Res 2010;11:84.
98. Sinn PL, Shah AJ, Donovan MD, et al. Viscoelastic gel formulations enhance airway epithelial gene transfer with viral vectors. Am J Respir Cell Mol Biol 2005;32:404-410.
99. Mitomo K, et al. Toward gene therapy for cystic fibrosis using a lentivirus pseudotyped with sendai virus envelopes. Mol Ther 2010;18:1173-1182.
100. Griesenbach U, et al. Assessment of F/HN-pseudotyped lentivirus as a clinically relevant vector for lung gene therapy. Am J Respir Crit Care Med 2012;186:846-856.
101. Sinn PL, Cooney AL, Oakland M, et al. Lentiviral vector gene transfer to porcine airways. Mol Ther Nucleic Acids 2012;1:e56.
102. Aiuti A, et al. The Committee for Advanced Therapies of the European Medicines Agency reflection paper on management of clinical risks deriving from insertional mutagenesis. Hum Gene Ther Clin Dev 2013;24:47-54.
103. Cavazzana-Calvo M, et al. Transfusion independence and HMGA2 activation after gene therapy of human b-thalassaemia. Nature 2010;467:318-322.
104. Caplen NJ, et al. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med 1995;1:39-46.
105. Gill DR, et al. A placebo-controlled study of liposomemediated gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther 1997;4:199-209.
106. Porteous DJ, et al. Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther 1997;4:210-218.
107. Noone PG, et al. Safety and biological efficacy of a lipid- CFTR complex for gene transfer in the nasal epithelium of adult patients with cystic fibrosis. Mol Ther 2000;1:105-114.
108. Ruiz FE, et al. A clinical inflammatory syndrome attributable to aerosolized lipid-DNA administration in cystic fibrosis. Hum Gene Ther 2001;12:751-761.
109. Zabner J, et al. Comparison of DNA-lipid complexes and DNA alone for gene transfer to cystic fibrosis airway epithelia in vivo. J Clin Invest 1997;100:1529-1537.
110. Konstan MW, et al. Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Hum Gene Ther 2004;15:1255-1269.
111. The U.K. Cystic Fibrosis Gene Therapy Consortium. www.cfgenetherapy.org.uk/genetherapy/article/CF-Gene-Therapy-Clinical-Trials (last accessed May 11, 2015).
112. McLachlan G, et al. Pre-clinical evaluation of three nonviral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung. Gene Ther 2011;18:996-1005.
113. Davies LA, Nunez-Alonso GA, McLachlan G, et al. Aerosol delivery of DNA/liposomes to the lung for cystic fibrosis gene therapy. Hum Gene Ther Clin Dev 2014;25: 97-107.
114. Hyde SC, et al. CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat Biotechnol 2008;26:549-551.
115. Horsley AR, et al. Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation. Thorax 2013;68: 532-539.
116. Alton EW, et al. The safety profile of a cationic lipidmediated cystic fibrosis gene transfer agent following repeated monthly aerosol administration to sheep. Biomaterials 2013;34:10267-10277.
117. Alton EW, et al. Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung. Gene Ther 2014;21:89-95.
118. Cox DB, Platt RJ, and Zhang F. Therapeutic genome editing: prospects and challenges. Nat Med 2015;21:121-131.
119. Schwank G, et al. Functional repair of CFTR by CRISPR/ Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell 2013;13:653-658.
120. Lee CM, Flynn R, Hollywood JA, et al. Correction of the DF508 mutation in the cystic fibrosis transmembrane conductance regulator gene by zinc-finger nuclease homology-directed repair. Biores Open Access 2012;1: 99-108.